Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) Vol. 108; no. 5; pp. 1429 - 1435
Main Authors: Bye, Alexander P, Kriek, Neline, Sage, Tanya, Rawlings, Suzannah J, Prodger, Catherine, Kesavan, Murali, Lees, Charlotte, Booth, Stephen, Cowen, Louise G, Shefferd, Kirsty, Desborough, Michael J, Gibbins, Jonathan M, Eyre, Toby A
Format: Journal Article
Language:English
Published: Italy Fondazione Ferrata Storti 01-05-2023
Ferrata Storti Foundation
Subjects:
Benzamides
Humans
Letter to the Editor
Leukemia, Lymphocytic, Chronic, B-Cell
Protein Kinase Inhibitors
Pyrazines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
Data is available on request.
Disclosures
APB designed the study, performed research, analysed data, and wrote the manuscript; NK performed research and analysed data; TS and SR performed research; CP collected and collated data; MK, CL, SB, LC and KS collected data; MJD, JMG and TAE designed the study and wrote the manuscript.
Contributions
APB has received unrelated research funding from Takeda. MJRD has received unrelated funding for teaching or advisory boards from Takeda, Pfizer, Portola, Sanofi, and Amgen. TAE has received unrelated funding for education, advisory boards or research from AstraZenica, Beigene, Janssen, Incyte, Secura Bio, KITE, Roche, Gilead and Abbvie; and funding from and steering committee for Loxo Oncology.
Data-sharing statement
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2022.281402